Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £5.37M
• Dividend Yield: N/A
• Average Volume (3M): 450.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.21
• Revenue Growth: 12.19%
• EPS Growth: 18.12%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 381,057
• 30 Day Avg. Volume: 450,303
• PEG Ratio: -0.08
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 2.05
• P/FCF Ratio: -9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £2.00
• Price Target Upside: -1.96% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: 2.00p ▼(-1.96% Downside)

Proteome Sciences' overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues, negative profitability, and high debt levels. The technical analysis further indicates a bearish trend with weak momentum. The negative P/E ratio and lack of dividend yield contribute to a weak valuation score. These factors collectively suggest high financial risk and limited investment appeal.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

How the Company Makes Money

Proteome Sciences generates revenue primarily through the sale of its proteomic services and products. Key revenue streams include contract research services for pharmaceutical and biotechnology companies, where they provide custom proteomics analysis and biomarker discovery services. Additionally, the company earns income from licensing its proprietary technologies and tools to other firms in the industry. Significant partnerships with academic institutions and collaborations with industry leaders also contribute to its earnings, as they often lead to joint research initiatives and shared funding opportunities.

Proteome Sciences Financial Statement Overview

Summary

Proteome Sciences is facing substantial financial challenges across all financial statements. Declining revenues, negative profitability, and high debt levels indicate significant business risks. The negative equity and cash flow issues further exacerbate the company's financial instability.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	-32.00K	670.00K	1.65M	4.77M	2.96M	2.58M
EBITDA	-1.45M	-1.51M	-1.14M	2.13M	625.00K	714.00K
Net Income	-3.33M	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	8.35M	9.21M	11.46M	12.43M	10.04M	9.09M
Cash, Cash Equivalents and Short-Term Investments	263.00K	1.13M	2.03M	3.99M	2.39M	2.21M
Total Debt	15.39M	14.52M	13.47M	11.91M	11.69M	11.04M
Total Liabilities	16.93M	15.72M	14.52M	13.28M	12.82M	12.45M
Stockholders Equity	-8.58M	-6.52M	-3.07M	-843.00K	-2.77M	-3.36M
Cash Flow
Free Cash Flow	-1.48M	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-1.21M	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-273.00K	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	368.00K	151.00K	-1.06M	-209.00K	-400.00K	-146.00K

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Neutral. The current price of 2.04 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.85, and below the 200-day MA of 3.43, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 39.56 is Neutral, neither overbought nor oversold. The STOCH value of 48.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£11.62M	―	-62.83%	―	27.60%	1.35%
IXI	54 Neutral	£10.89M	―	-13.85%	―	7.27%	39.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£2.51M	―	-321.90%	―	125.37%	22.47%
GENI	49 Neutral	£10.33M	―	-181.41%	―	12.12%	54.24%
OBD	44 Neutral	£11.55M	―	-333.59%	―	45.22%	55.71%
PRM	41 Neutral	£5.37M	―	―	―	12.19%	18.12%

Proteome Sciences Corporate Events

Proteome Sciences Announces Successful AGM Resolutions

Proteome Sciences announced that all resolutions were passed at their Annual General Meeting, indicating strong shareholder support and a stable governance structure. This outcome reinforces the company’s strategic direction and could positively impact its market position in the proteomics industry, benefiting stakeholders by ensuring continued focus on innovative drug discovery and biomarker identification services.

Proteome Sciences Sees Strong Recovery and Growth Prospects

At its Annual General Meeting, Proteome Sciences announced a continued recovery in the pharmaceutical and biotech markets, with a strong pipeline of orders extending into 2026. The company is progressing with licensing discussions for new DXT tags and has completed its first commercial single cell proteomics project. The increased demand has led to full capacity utilization at their Frankfurt site, positioning the company for substantial future revenue growth.